A phase I clinical trial to evaluate the tolerability and the pharmacokinetics of CKD-348.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
H plus Yangji hospital
Seoul, South Korea
AUCt of CKD-348(4) F1 and CKD-348(4) F2
AUCt: Area under the concentration-time curve from time zero to time
Time frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
Cmax of CKD-348(4) F1 and CKD-348(4) F2
Maximum plasma concentration of the drug
Time frame: Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.